Table 1 Characteristics of patients diagnosed with hormone receptor-positive breast cancer before the age of 85 years in Girona and Tarragona, 2007 to 2009.

From: Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred

 

HER2 − (N = 1185;75.3%)

HER2 + (N = 388;24.7%)

Total (N = 1573; 100%)

p-value

Registry, n (%)

Girona

599 (50.5%)

208 (53.6%)

807 (51.3%)

0.29a

Tarragona

586 (49.5%)

180 (46.4%)

766 (48.7%)

Age

Mean (SD)

58.9 (12.9)

57.4 (13.2)

58.3 (13.1%)

0.87 b

Age groups, n (%)

0–49 years

329 (27.8%)

121 (31.2%)

450 (28.6%)

0.32a

50–59 years

291 (24.6%)

103 (26.5%)

394 (25.1%)

 

60–74 years

389 (32.8%)

113 (29.1%)

502 (31.9%)

 

75–84 years

176 (14.9%)

51 (13.1%)

227 (14.4%)

 

Stage

I

473 (39.9%)

116 (29.9%)

589 (37.4%)

 < 0.05a

II

416 (35.1%)

160 (41.2%)

576 (36.6%)

 

III

183 (15.4%)

70 (18.0%)

253 (16.1%)

 

IV

57 (4.8%)

26 (6.7%)

83 (5.3%)

 

Missing

56 (4.7%)

16 (4.1%)

72 (4.6%)

 

Estrogen, n (%)

 − 

24 (2.0%)

8 (2.1%)

32 (2.0%)

0.96a

 + 

1161 (98.0%)

380 (97.9%)

1541(98.0%)

 

Missing

0

0

0

 

Progesterone, n (%)

 − 

135 (11.5%)

42 (11.0%)

177 (11.8%)

0.95a

 + 

1041 (88.5%)

346 (89.0%)

1385 (88.1%)

 

Missing

9

2

11 (0.7%)

 

HER2, n (%)

 − 

1185 (100.0%)

0 (0.0%)

1185 (75.3%)

–

 + 

0 (0.0%)

388 (100.0%)

388 (24.7%)

 

Missing

0

0

0

 

Ki67

Missing, n

868 (73.4%)

279 (97.6%)

1147 (72.9%)

 < 0.05 a

Mean (SD)

23.3 (19.2)

26.1 (17.9)

24.7 (18.9)

 

Inclusion criterionc

1072 (75.6%)

346 (24.4%)

1418 (100%)

 

Adherence

No: ≤ 80%

146 (13.6%)

53 (15.4%)

199 (14.0%)

0.47 a

Yes: > 80%

810 (75.5%)

259 (75.1%)

1069 (75.4%)

 

Data not availabled

117 (10.9%)

33 (9.6%)

150 (10.6%)

 

Patients with no missing

Data (N)e

955 (75.3%)

313 (24.7%)

1268 (100.0%)

 

Deceased (%)f

5-year, all causes (N, %)

96 (10.1%)

32 (10.1%)

153 (10.7%)

0.68 a

10-year, all causes (N, %)

173 (18.1%)

57 (19.3%)

230 (18.1%)

 

Years follow-up (mean, SD) g

9.3 (1.8)

9.4 (1.7)

9.3 (1.8)

0.91 b

  1. achi-square test, bt-test, cInclusion criterion: patients diagnosed in stages I, II or III, dPatients with no data available on adherence to endocrine treatment among patients who met the inclusion criterion n = 1418, ePatients with no missing data among those who met the inclusion criterion who were included in the statistical modeling, fnumber of deaths at 5 and 10 years of follow-up among the N = 1268 patients included in the modeling, gfollow-up of the N = 1268 patients included in the modeling.
  2. Significant values are in bolditalics.
Back to article page